These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 29397323)
21. Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis. Nomura O; Osada T; Shibuya T; Ishikawa D; Haga K; Kodani T; Sakamoto N; Ogihara T; Yamaji K; Watanabe S J Clin Apher; 2018 Feb; 33(1):21-28. PubMed ID: 28581039 [TBL] [Abstract][Full Text] [Related]
22. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment. Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767 [No Abstract] [Full Text] [Related]
23. The safety of vedolizumab for the treatment of ulcerative colitis. Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302 [TBL] [Abstract][Full Text] [Related]
26. Combination of vedolizumab and immunomodulators in ulcerative colitis. Pinton P J Gastroenterol Hepatol; 2021 Dec; 36(12):3556. PubMed ID: 34519096 [No Abstract] [Full Text] [Related]
28. Resolution of CMV Infection in the Bowel on Vedolizumab Therapy. Rawa-Gołębiewska A; Lenarcik M; Zagórowicz E J Crohns Colitis; 2019 Sep; 13(9):1234-1235. PubMed ID: 30860256 [No Abstract] [Full Text] [Related]
29. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. Hagan M; Cross RK Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111 [TBL] [Abstract][Full Text] [Related]
30. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Boden EK; Shows DM; Chiorean MV; Lord JD Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476 [TBL] [Abstract][Full Text] [Related]
32. Ulcerative Colitis: Update on Medical Management. Iskandar HN; Dhere T; Farraye FA Curr Gastroenterol Rep; 2015 Nov; 17(11):44. PubMed ID: 26386686 [TBL] [Abstract][Full Text] [Related]
33. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768 [TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. Jin Y; Lin Y; Lin LJ; Zheng CQ World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371 [TBL] [Abstract][Full Text] [Related]
35. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. Nakano R; Iwakiri R; Ikeda Y; Kishi T; Tsuruoka N; Shimoda R; Sakata Y; Yamaguchi K; Fujimoto K J Gastroenterol Hepatol; 2013 Feb; 28(2):303-8. PubMed ID: 23339387 [TBL] [Abstract][Full Text] [Related]
36. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Cytapheresis for Ulcerative Colitis in Special Situations: Delayed Onset of Optimum Efficacy in Elderly Patients. Shibuya T; Nomura O; Nomura K; Okahara K; Haga K; Ishikawa D; Sakamoto N; Ogihara T; Osada T; Nagahara A Digestion; 2020; 101(1):46-52. PubMed ID: 31722366 [TBL] [Abstract][Full Text] [Related]
38. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO) Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369 [TBL] [Abstract][Full Text] [Related]
39. Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis? Yamamoto T Aliment Pharmacol Ther; 2023 Sep; 58(5):546-547. PubMed ID: 37559519 [No Abstract] [Full Text] [Related]
40. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. Scribano ML World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]